Akari Therapeutics, Plc (AKTX)
NASDAQ: AKTX · Real-Time Price · USD
1.270
-0.030 (-2.31%)
At close: Mar 28, 2025, 4:00 PM
1.250
-0.020 (-1.57%)
After-hours: Mar 28, 2025, 4:04 PM EDT
Company Description
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.
Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities.
The company also develops PASylated-nomacopan, which is in preclinical development for the treatment of geographic atrophy secondary to dry age-related macular degeneration; and hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA) combined with nomacopan, which is in phase 3 clinical development for the treatment of pediatric HSCT-TMA.
The company is headquartered in Boston, Massachusetts.
Akari Therapeutics, Plc
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 12 |
| CEO | Samir Patel |
Contact Details
Address: 22 Boston Wharf Road, Floor 7 Boston, Massachusetts 02210 United States | |
| Phone | 929 274 7510 |
| Website | akaritx.com |
Stock Details
| Ticker Symbol | AKTX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001541157 |
| CUSIP Number | 00972G108 |
| ISIN Number | US00972G2075 |
| Employer ID | 98-1034922 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Samir Rashmikant Patel M.D. | President, Chief Executive Officer and Director |
| Dr. Torsten Hombeck Ph.D. | Chief Financial Officer |
| Dr. Miles Nunn | Chief Scientific Officer |
| Dr. Satyajit Mitra Ph.D. | Executive Director and Head of Oncology |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 20, 2025 | 8-K | Current Report |
| Mar 3, 2025 | 8-K | Current Report |
| Feb 14, 2025 | SCHEDULE 13G | Filing |
| Feb 14, 2025 | SCHEDULE 13D/A | Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Dec 18, 2024 | 8-K | Current Report |
| Dec 16, 2024 | 8-K | Current Report |
| Dec 12, 2024 | 8-K | Current Report |
| Dec 6, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Nov 19, 2024 | 10-Q | Quarterly Report |